Summary Global Markets Direct’s, Neurofibromatoses - Pipeline Review, H2 2012,provides an overview of the indication’s therapeutic pipeline. This reportprovides information on the therapeutic development forNeurofibromatoses, complete with latest updates, and special features onlate-stage and discontinued projects. It also reviews key players involved inthe therapeutic development for Neurofibromatoses. Neurofibromatoses -Pipeline Review, Half Year is built using data and information sourced fromGlobal Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releasesfrom company/university sites and industry-specific third party sources,put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based onthe availability and relevance of data for the indicated disease.
Scope - A snapshot of the global therapeutic scenario for Neurofibromatoses.- A review of the Neurofibromatoses products under development by companiesand universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Neurofibromatoses.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.- Devise corrective measures for pipeline projects by understandingNeurofibromatoses pipeline depth and focus of Indication therapeutics.
Table of Contents : List of Tables 6List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Neurofibromatoses Overview 8Therapeutics Development 9An Overview of Pipeline Products for Neurofibromatoses 9Neurofibromatoses Therapeutics under Development by Companies 11Neurofibromatoses Therapeutics under Investigation byUniversities/Institutes 12Mid Clinical Stage Products 14Comparative Analysis 14Early Clinical Stage Products 15Comparative Analysis 15Discovery and Pre-Clinical Stage Products 16Comparative Analysis 16Neurofibromatoses Therapeutics – Products under Development byCompanies 17Neurofibromatoses Therapeutics – Products under Investigation byUniversities/Institutes 18………………….
Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=PipelineReview, H2 2012&PubId=&pagenum=1
For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: email@example.com ,firstname.lastname@example.orgURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore